Page 22 - DIAGEN

Hermatology primeFISH Products

HEMATOLOGY

PANEL

17-093 IGH-MYEOV t(11;14)

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin IGH rearrange ments in other neoplasms, those found
lymphoma (NHL) with an aggressive clini cal course. it is in MM have IGH breakpoints predominantly in the C/J
genetically characterized by t(ll;l4)(ql3;q32) found in ap- region, placing the MYEOV gene under the control of the
proximately 95% of MCL patients. Less frequently, t(ll;l4) 3’ Eal enhancer when in the MYEOV state. in contrast to
can also be detected in B-cell prolymphocytic leukemia, CCNDl translocations, the Eµ enhancer controls CCNDl
my elomas, and chronic lymphocytic leukemia. The t(ll;l4) expression. MYEOV overexpression may be a possible
(ql3;q32) translocation is the most common translocation prognostic factor in MM.
in MM, occurring in approximately 15% of cases. Unlike

TRANSLOCATION
SHGC-140404 D11S2927
3' 5'
Gen Tel
CCND1
1.1 mb
NORMAL
11q13.3

RH98285 SHGC-106213
3' 5' TRANSLOCATION
Gen Tel
IGH

1.5 mb
14q12.33

(Not to scale) TRANSLOCATION

www.diagen.com.tr References
Ronchetti et al., Blood 1999 93(4):1330-1337
Moreaux et al., Exp Haematol 2010;38(12):1189-1198
Bentz et al (2004) Canc Cytopath 102:124-131
Fonseca et al., Leukemia 2009;23(12):2210-2221
Jares et al (2012) J Clin Invest 122:3416-3423

22 PRODUCT CATALOGUE info@diagen.com.tr